Back to Search
Start Over
Activated factor XI-antithrombin complex presenting as an independent predictor of 30-days mortality in out-of-hospital cardiac arrest patients
- Source :
- Thrombosis Research, Thrombosis Research, 204, 1-8. Elsevier Science
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- BACKGROUND: Cardiac arrest and cardiopulmonary resuscitation (CPR) are associated with activated coagulation and microvascular fibrin deposition with subsequent multiorgan failure and adverse outcome.OBJECTIVES: Activated Factor XI-antithrombin (FXIa-AT) complex, activated Factor IX-antithrombin (FIXa-AT) complex and thrombin-antithrombin (TAT) complex were measured as markers of coagulation activation, and evaluated as independent prognostic indicators in out-of-hospital cardiac arrest (OHCA) patients.METHODS: From February 2007 until December 2010 blood samples were collected in close approximation to CPR from patients with OHCA of assumed cardiac origin. Follow-up samples in survivors were drawn 8-12 h and 24-48 h after hospital admission. All measurements were determined by ELISA.RESULTS: Thirty-seven patients presented with asystole and 77 with ventricular fibrillation as first recorded heart rhythm. At 30-days follow-up, 70 patients (61.4%) had died. All patients had elevated levels of FXIa-AT complex, FIXa-AT complex and TAT. Initial levels were significantly higher in non-survivors compared to 30-days survivors. A significant increase in risk of 30-days all-cause mortality was observed through increasing quartiles of all three biomarkers in univariate Cox regression analysis. Compared to the lowest quartile (Q1), only FXIa-AT complex levels in Q3 (HR 3.17, p = 0.011) and Q2 (HR 3.02, p = 0.016) were independently associated with all-cause mortality in the multivariable analysis. FIXa-AT complex and TAT-complex did not behave as independent predictors.CONCLUSIONS: Complexes of FXIa-AT were independently associated with 30-days survival in OHCA-patients.CLINICAL TRIAL REGISTRATION: ClinicalTrials. gov, NCT02886273.
- Subjects :
- medicine.medical_specialty
Resuscitation
medicine.medical_treatment
INHIBITION
030204 cardiovascular system & hematology
Antithrombins
Factor XIa
03 medical and health sciences
0302 clinical medicine
AMERICAN-HEART-ASSOCIATION
Factor XIa-antithrombin complex
Internal medicine
medicine
Coagulopathy
Humans
Cardiopulmonary resuscitation
Asystole
Coagulation activation
RISK
COAGULOPATHY
Out-of-hospital cardiac arrest
Thrombin-antithrombin complex
RESUSCITATION
STATEMENT
business.industry
Proportional hazards model
Antithrombin
Factor IXa-antithrombin complex
Hematology
Prognosis
medicine.disease
Cardiopulmonary Resuscitation
COAGULATION-FACTOR XI
Quartile
INTERNATIONAL LIAISON COMMITTEE
030220 oncology & carcinogenesis
Ventricular fibrillation
SURVIVAL
Cardiology
business
CARDIOPULMONARY
medicine.drug
Subjects
Details
- ISSN :
- 00493848
- Volume :
- 204
- Database :
- OpenAIRE
- Journal :
- Thrombosis Research
- Accession number :
- edsair.doi.dedup.....5f07ae02d67ca75dfd400bc9bd1ad01a
- Full Text :
- https://doi.org/10.1016/j.thromres.2021.05.014